Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARABELA neoadjuvant breast cancer study
2019-002123-15Phase 2Active
- Sponsor
- GEICAM
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib and letrozole in breast cancer, estrogen receptor-positive breast cancer and hormone receptor-positive/HER2-negative breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Residual Cancer Burden 0-I rate. Started May 2020; status: active.
02
Drugs
abemaciclibletrozole
03
Conditions
breast cancerestrogen receptor-positive breast cancerhormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on 2019-002123-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002123-15.